2026 Summer School on Multidisciplinary Management of Neuromuscular Diseases
CPD-Accredited Webinar | Emerging Insights Into AAV‑Mediated Gene Therapy: Understanding Hepatotoxicity and Implications for Neuromuscular Disorders
ENMC Workshop 298: Clinical care guidelines, outcome measures, and clinical trial readiness in Oculopharyngeal Muscular Dystrophy (OPMD).
TREAT-NMD LGMD Masterclass
Physiotherapy and Occupational Therapy Community of Practice Knowledge Sharing Session
15th International Myotonic Dystrophy Consortium Meeting (IDMC-15)
Join the international myotonic dystrophy research community at the 15th meeting of the International Myotonic Dystrophy Consortium (IDMC-15)! The event will take place from May 26th to May 30th 2026, in the picturesque Saguenay—Lac-Saint-Jean region in Quebec. View Preliminary Programme or View Guidelines.
Registration is open until April 20.
Location: Hôtel Le Montagnais, Chicoutimi, Québec, Canada
The annual conference of the International Myotonic Dystrophy Consortium brings together world-renowned experts, researchers, healthcare professionals, patient advocates, people living with the disease and representatives from the pharmaceutical industry to share their knowledge and collaborate on neuromuscular disease research.
What’s New:
- Late‑breaking abstracts: Submissions are invited for a dedicated session featuring recent, unpublished scientific and clinical advances in myotonic dystrophy research.
- On‑site information: Practical travel and stay details are now available to help you prepare for Saguenay.
A maximum of four abstracts will be selected for oral presentations. Each selected abstract will be presented in a 10-minute talk with a 5-minute discussion.
We welcome submissions from academic, clinical, and industry, including:
- New or updated results from clinical trials or observational studies
- Translational or biomarker discoveries
- Innovative therapeutic approaches
- Findings with potential impact on clinical practice or patient outcomes
Submission requirements
- Abstracts must include recent, unpublished, non-public data
- Submissions are open to academic, clinical, and industry-led studies
- Selected authors will be notified in advance to allow preparation
All submissions will undergo expedited review by the scientific committee, based on scientific quality, novelty, and relevance.
This session offers a unique platform to share cutting-edge findings and accelerate progress in myotonic dystrophy research and care. For More Information: